Patients & Caregivers
Bioverativ and Bicycle Therapeutics Partner for Rare Blood Disease Research
Bioverativ will collaborate with Bicycle Therapeutics to research, develop and commercialize sickle cell and hemophilia treatments.
WWE Raises Funds for Pediatric Cancer Research
To observe Pediatric Cancer Awareness Month, the WWE is partnering with the V Foundation through Connor’s Cure to raise funds for pediatric cancer research.
FDA Grants Orphan Drug Designation to Glioblastoma Multiforme and Anaplastic Astrocytoma Treatment
The Food and Drug Administration (FDA) has granted orphan drug designation to DCC-2618 for the treatment of glioblastoma multiforme and anaplastic astrocytoma.
FDA Approves Acute Myeloid Leukemia Treatment
This morning, the U.S. Food and Drug Administration (FDA) approved Pfizer’s Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML).
Janet Woodcock Issues Statement on Safety Concerns Regarding Keytruda
Woodcock: We are communicating now to remind doctors and patients that Keytruda is not approved for treating multiple myeloma
Is Kyprolis Better Than Velcade for Treating Relapsed Multiple Myeloma?
Post-hoc analysis showed that Kyprolis + dex increased overall survival by 7.6 months compared to Velcade + dex
Actemra Gets FDA Approval for Cytokine Release Syndrome Treatment
On the same day that the first CAR-T-based
was approved, the FDA has approved a drug to help with a life-threatening side effect associated of it.
FDA Approves First Gene Therapy
The U.S. Food and Drug Administration made history today when they approved the first-ever gene therapy, Kymriah (tisagenlecleucel), developed by Novartis.
FDA and EMA Accept Regulatory Submissions for Chronic Myeloid Leukemia Treatment
Based on positive results from a Phase 3 head-to-head trial, the FDA and EMA have accepted the supplemental New Drug Application for Bosulif (bosutinib).
Radioactive Somatostatin Analog Under Review by FDA (Again) to Treat Neuroendocrine Tumors
Lutathera, the 177-Lu somatostatin analog, is a new form of targeted therapy.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.